Patient with Atypical Neurocytoma – Case Report
Authors:
D. Vrána 1,2; K. Cwiertka 1; L. Lukešová 1; O. Kalita 3; J. Ehrmann 4; S. Buřval 5; P. Koranda 6
Authors place of work:
Onkologická klinika LF UP a FN Olomouc
1; Oddělení toxikogenomiky, Centrum toxikologie a zdravotní bezpečnosti, SZÚ Praha
2; Neurochirurgická klinika LF UP a FN Olomouc
3; Ústav klinické a molekulární patologie LF UP v Olomouci
4; Radiologická klinika LF UP a FN Olomouc
5; Klinika nukleární medicíny LF UP a FN Olomouc
6
Published in the journal:
Klin Onkol 2013; 26(5): 362-364
Category:
Kazuistika
Summary
Background:
Neurocytoma represents a rare tumor of the central nervous system usually slowly growing and generally with good prognosis after surgical resection with or without adjuvant radiotherapy.
Case:
A 25‑year‑ old woman presented with sudden fainting. During the initial workup, brain CT was completed with finding of tumor inside the third ventricle spreading into both lateral ventricles. The patient underwent partial surgical resection followed by radical gross resection, no adjuvant radiotherapy was indicated during the initial treatment and the patient was followed up with regular brain MRIs and clinical examinations. Thirty‑ six months after the initial resection, there was progression on MRI and radiotherapy was recommended. At this moment, patient is 12 months after radiotherapy with stable disease on MRI and with good stable performance status.
Conclusion:
One of the greatest problems in the management of neurocytoma is the timing of adjuvant radiotherapy. From published data, it is clear that adjuvant radiotherapy increases local control; however, this has to be considered carefully against the possible risks from late side effects of radiotherapy considering long-time survival of the patients.
Key words: Submitted: Accepted:
neurocytoma – radiotherapy – proliferative index – brain tumors
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
7. 5. 2013
4. 6. 2013
Zdroje
1. Hassoun J, Gambarelli D, Grisoli F et al. Central neurocytoma. An electron‑ microscopic study of two cases. Acta Neuropathol 1982; 56(2): 151– 156.
2. Hassoun J, Söylemezoglu F, Gambarelli D et al. Central neurocytoma: a synopsis of clinical and histological features. Brain Pathol 1993; 3(3): 297– 306.
3. Uzis.cz [internetová stránka]. Ústav zdravotnických informací a statistiky ČR. Novotvary 2009 ČR. Dostupné z: http://www.uzis.cz/book/export/html/5007.
4. Sim FJ, Keyoung HM, Goldman JE et al. Neurocytoma is a tumor of adult neuronal progenitor cells. J Neurosci 2006; 26(48): 12544– 12555.
5. Rades D, Fehlauer F, Schild S et al. Treatment for central neurocytoma: a meta‑analysis based on the data of 358 patients. Strahlenther Onkol 2003; 179(4): 213– 218.
6. Rades D, Schild SE, Ikezaki K et al. Defining the optimal dose of radiation after incomplete resection of central neurocytomas. Int J Radiat Oncol Biol Phys 2003; 55(2): 373– 377.
7. Nakagawa K, Aoki Y, Sakata K et al. Radiation therapy of well‑differentiated neuroblastoma and central neurocytoma. Cancer 1993; 72(4): 1350– 1355.
8. Kulkarni V, Rajshekhar V, Haran RP et al. Long‑term outcome in patients with central neurocytoma following stereotactic biopsy and radiation therapy. Br J Neurosurg 2002; 16(2): 126– 132.
9. Rades D, Schild SE. Is 50 Gy sufficient to achieve long‑term local control after incomplete resection of typical neurocytomas? Strahlenther Onkol 2006; 182(7): 415– 418.
10. von Koch CS, Schmidt MH, Uyehara‑Lock JH et al. The role of PCV chemotherapy in the treatment of central neurocytoma: Illustration of a case and review of the literature. Surg Neurol 2003; 60(6): 560– 565.
11. Kala M, Cwiertka K, Hajduch M. Nové trendy v chemoterapii nádorů mozků – léčba dle histologických diagnóz. Klin Onkol 2000; 13(4): 107– 111.
12. Buchbinder D, Danielpour M, Yong WH et al.Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue. J Neurooncol 2010; 97(3): 429– 437.
Štítky
Detská onkológia Chirurgia všeobecná OnkológiaČlánok vyšiel v časopise
Klinická onkologie
![Číslo 5](https://www.prelekara.sk/media/cache/resolve/journal_issue/media/image_pdf/e218ca1652e9adba76c526568949cf56.jpeg)
2013 Číslo 5
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Tramadol a paracetamol v tlumení poextrakční bolesti
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
- Je použití metamizolu během prvního trimestru gravidity bezpečné?
Najčítanejšie v tomto čísle
- Léčba infekcí u pacientů v paliativní symptomatické a terminální fázi onkologického onemocnění
- Chylózní ascites jako závažná komplikace neuroendokrinního tumoru ilea – kazuistika
- Nefroblastom – 30 let léčby ve Fakultní nemocnici v Motole
- Pacientka s atypickým neurocytomem – kazuistika